Our Latest Diagnostic Services: Tissue Based Assays and New Neurology Panels
As we welcome a new year, Wieslab Diagnostic Services is proud to introduce a suite of powerful new diagnostic tools developed to support clinicians, facilitate effective diagnosis, and improve outcomes for patients with complex neuroinflammatory and neuromuscular conditions.
Tissue-Based Assays – Neuronal Antibody Screening
Test 200
One of the first services of its kind offered in Europe, our tissue‑based assay (TBA) service uses immunofluorescence to screen for a wide range of neuronal autoantibodies, offering a broad view of neuro inflammatory activity. The distinct antibody patterns identified in the TBA guide targeted confirmation with antigen‑specific tests, providing a clear two-step diagnostic regimen which is especially valuable in complex or time‑critical presentations.
In contrast to standard single-target autoantibody testing, using a TBA + confirmatory antigen-specific assay improves both sensitivity and specificity, saves valuable clinical time, and reduces the significant risk of misdiagnosis in patients with complex neuroinflammatory presentations.
Autoantibodies in Dementia‑Like Conditions
Panel 502
Swift, accurate identification of autoimmune dementia is essential to minimize tissue damage and preserve function in patients. Because the condition is driven by inflammation, immunomodulating treatment can be effective and the disease is potentially reversible, making early diagnosis and intervention critical.
Yet distinguishing autoimmune dementia from neurodegenerative dementia is often challenging. Presentations frequently look similar, and in autoimmune cases symptoms can progress quickly, so timely and reliable testing is key to successful patient management.
Panel 502 is designed to meet this need, screening for a curated set of antibodies known to cause dementia‑like conditions. The results equip clinicians to distinguish autoimmune disease from neurodegeneration and to initiate targeted therapies promptly, with the potential to meaningfully improve patient outcomes.
Inflammatory Neuropathy Screen – extended analysis
Panel 506
Panel 506 is built for the early assessment of suspected immune mediated polyneuropathies, where different conditions often present similarly and disease can progress rapidly. The panel consolidates key autoantibody markers (including gangliosides and nodal/paranodal targets) to support differential diagnosis and gauge disease activity. It also includes neurofilament light (NfL) - a blood marker of axonal injury that helps clinicians assess ongoing neuroaxonal loss and the urgency for intervention.
Panel 506 is available for both standard and urgent (48hr) testing, allowing clinicians to move quickly in time-sensitive cases. By delivering consolidated, mechanism‑oriented diagnostics in a clinically relevant timeframe the panel helps clinicians differentiate look‑alike neuropathies, judge the extent of immune‑mediated injury, and move more rapidly toward the most appropriate therapy to preserve motor and sensory function.
Ganglioside Antibodies - 48hr Urgent Testing
Panel 546
Inflammatory neuropathies associated with ganglioside antibodies are often progressive, making rapid differential diagnosis essential to support early and accurate decision‑making in treatment.
To support this need, Wieslab is launching an urgent testing (48-hour turnaround time) option for the 546 ganglioside antibody panel, helping clinical teams confirm an immune‑mediated mechanism is present and differentiate overlapping neuropathy phenotypes to allow earlier initiation of appropriate immunotherapies.
Why This Matters for Clinicians and Patients
Across the field of neurology, speed and precision are essential. These new tests are built to reduce diagnostic delay, increase confidence in differential diagnosis, and facilitate earlier treatment to improve patient outcomes.
Stay Updated
Sign up for the newsletter to keep informed about new diagnostic capabilities at Wieslab, and updates on scientific data and presentations.
